Overview

Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis

Status:
Completed

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to learn more about the immune response to etanercept produced using a modified process in patients with plaque psoriasis.

Phase:

Phase 4

Details

Lead Sponsor:

Amgen

Treatments:

Etanercept